Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin alfa vs Epoetin alfa in chemotherapy-induced anemia
NCT00148421Phase 3Completed
- Sponsor
- Amgen
- Modality
- Erythropoietins, Colony Stimulating Factors
01
Overview
Phase 3, randomised, open-label trial of darbepoetin alfa in anemia (2 arms), sponsored by Amgen. Primary endpoint: Incidence of red blood cell transfusions. Status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00148421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00148421.